Skip to Main Content

Author Details

David W Cescon
Princess Margaret Cancer Centre
2003
122
37
PMIDPaper TitleJournal TitlePublished Year
38095672Detection of metabolic adaptation in a triple-negative breast cancer animal model with [<sup>18</sup>F]choline-PET imaging as a surrogate for drug resistance.Eur J Nucl Med Mol Imaging2024
38070159Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.J Natl Cancer Inst2024
37992310A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.Clin Cancer Res2024
35302667Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.Hepatology2023
37526149TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.Future Oncol2023
37847590Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages.Cell Rep2023
37511178Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Int J Mol Sci2023
37987734Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.Cancer Res2023
37883228Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages.Cell Rep2023
37502925Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.Res Sq2023
37243731Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis.JNCI Cancer Spectr2023
37099733Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.JCO Precis Oncol2023
37065483Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential.Front Genet2023
36722142Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.Mol Cancer Ther2023
36792122Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review.J Immunother Cancer2023
34623509Novel classes of immunotherapy for breast cancer.Breast Cancer Res Treat2022
35705312Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.J Immunother Cancer2022
35578032PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.Nat Chem Biol2022
35857659Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.N Engl J Med2022
35750695Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.Nat Commun2022
35658519Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?J Clin Oncol2022
36547192Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.Curr Oncol2022
36280687Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins.Nat Commun2022
36108220Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer.Cancer Discov2022
36176758Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer.Cancer Drug Resist2022
36070391The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER<sup>+</sup> breast cancer with mitotic aberrations.Sci Adv2022
36033445Patient-derived cancer models: Valuable platforms for anticancer drug testing.Front Oncol2022
36287201<sup>90</sup>Y-Labeled Gold Nanoparticle Depot (NPD) Combined with Anti-PD-L1 Antibodies Strongly Inhibits the Growth of 4T1 Tumors in Immunocompetent Mice and Induces an Abscopal Effect on a Distant Non-Irradiated Tumor.Mol Pharm2022
35977349Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.JCO Precis Oncol2022
35914158CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.Proc Natl Acad Sci U S A2022
34890802Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications.Crit Rev Oncol Hematol2022
35223447Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches.Front Oncol2022
35304464Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids.Nat Commun2022
35301950Current Treatment and Future Trends of Immunotherapy in Breast Cancer.Curr Cancer Drug Targets2022
34903444Development of novel agents for the treatment of early estrogen receptor positive breast cancer.Breast2022
34965943Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.Clin Cancer Res2022
34931041No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.Br J Cancer2022
34556523Mutations in Noncoding <i>Cis</i>-Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer.Mol Cancer Res2022
34731350Breast cancer immune microenvironment: from pre-clinical models to clinical therapies.Breast Cancer Res Treat2022
34636180Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies.Adv Healthc Mater2022
33306920On the Road to Precision: Understanding the Biology Driving Genomic Assays.J Clin Oncol2021
33602786Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced <i>N</i>-glycosylation Abundance and Branching.Cancer Res2021
33676605Pembrolizumab monotherapy in metastatic triple-negative breast cancer.Lancet Oncol2021
33866248Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer.Breast2021
34555836Accelerating drug access from advanced to early breast cancer: the special case of oral selective estrogen receptor degraders.Curr Opin Oncol2021
34788078Assessing therapy response in patient-derived xenografts.Sci Transl Med2021
34678412PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.Ann Oncol2021
34093837Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.J Cancer2021
32566743Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study.NPJ Breast Cancer2020
35122035Circulating tumor DNA and liquid biopsy in oncology.Nat Cancer2020
  • 1 - 50 of 122

Recommended Authors

Chiara Corti
University of Milano
Career Start Year 2017
Number of shared co-authors 2
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 7
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 4
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 5
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 4
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 4
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 2
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 4
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 6
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 3
Sara M Tolaney
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 5
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 6
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 5
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 2
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 4
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 11
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 6
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 2
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 1
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 8
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 6
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 2
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 4
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 6
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 1
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Career Start Year 1987
Number of shared co-authors 9
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 3
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 3
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 4

Collaborators

Tak W Mak
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 27
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 18
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 12
Andrew Wakeham
Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network
Co-authored papers 10
Chiara Gorrini
Division of Clinical Studies, The Institute of Cancer Research
Co-authored papers 9
Andrew J Elia
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 8
Mathieu Lupien
Princess Margaret Cancer Research Centre
Co-authored papers 8
Wail Ba-Alawi
Princess Margaret Cancer Centre, University Health Network, University Ave.
Co-authored papers 8
Hal K Berman
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Geoffrey Liu
The Princess Margaret Cancer Centre/University of Toronto
Co-authored papers 7
Jennifer Cruickshank
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Co-authored papers 7
Wei Xu
Princess Margaret Cancer Centre
Co-authored papers 5
Rita Nanda
Co-authored papers 5
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Ming-Sound Tsao
University Health Network, University of Toronto
Co-authored papers 5
Linda Z Penn
University of Toronto
Co-authored papers 5
Arvind Singh Mer
University of Ottawa
Co-authored papers 5
Jeff P Bruce
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Rama Khokha
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Zhaleh Safikhani
Princess Margaret Cancer Center, University Health Network
Co-authored papers 4
Daniel D De Carvalho
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Katherine A Siminovitch
University of Toronto, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital
Co-authored papers 4
Samah El Ghamrasni
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Frances A Shepherd
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 3
Cheryl H Arrowsmith
University of Toronto
Co-authored papers 3
Thorsten Berger
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 3
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 3
Daniel Schramek
University of Toronto
Co-authored papers 3
Clement Ma
Co-authored papers 3
Release 1.2